Zinātniskās darbības atbalsta sistēma
Latviešu English

Publikācija: Clinicopathological Characteristics of Epstein-Barr Virus-Positive Gastric Cancer in Latvia

Publikācijas veids Zinātniskais raksts, kas indeksēts Web of science un/vai Scopus datu bāzē
Pamatdarbībai piesaistītais finansējums Pētniecības projekti
Aizstāvēšana: ,
Publikācijas valoda English (en)
Nosaukums oriģinālvalodā Clinicopathological Characteristics of Epstein-Barr Virus-Positive Gastric Cancer in Latvia
Pētniecības nozare 3. Medicīnas un veselības zinātnes
Pētniecības apakšnozare 3.1. Medicīnas bāzes zinātnes, tai skaitā farmācija
Pētniecības platforma Neviena
Autori E. Gasenko
S. Isajevs
M.C. Camargo
G.J.A. Offerhaus
Inese Poļaka
M.L. Gulley
R. Skapars
A. Sivins
I. Kojalo
Arnis Kiršners
D. Santare
J. Pavlova
O. Sjomina
E. Liepina
L. Tzivian
C.S. Rabkin
M. Leja
Atslēgas vārdi
Anotācija Epstein-Barr virus (EBV)-associated gastric cancer has been proposed to be a distinct gastric cancer molecular subtype. The prognostic significance of EBV infection in gastric cancer remains unclear and needs further investigation. Our study aimed to analyze EBV-positive and EBV-negative gastric cancer patients regarding their personal and tumor-related characteristics, and compare their overall survival. METHODS: Gastric cancer patients consecutively treated at the Riga East University Hospital during 2009-2016 were identified retrospectively. Tumor EBV status was determined by in-situ hybridization for EBV-encoded RNA (EBER). Information about clinicopathological characteristics was obtained from patient questionnaires, hospital records. Overall survival was ascertained through 30 July 2017. Cox proportional hazard regression models adjusted for personal and tumor-related covariates compared survival between EBV-positive and EBV-negative patients. RESULTS: There were a total of 302 gastric cancer patients (61% males) with mean and SD age 63.6 ± 11.5 years. EBER positivity was present in 8.6% of tumors. EBV-positive gastric cancer patients had better survival at 80 months [adjusted hazard ratio = 0.37, 95% confidence interval (CI) = 0.19-0.72] compared to EBV-negative patients. Worse survival was observed for patients with stage III (hazard ratio = 2.76, 95% CI = 1.67-4.56) and stage IV (hazard ratio = 10.02, 95% CI = 5.72-17.57) compared to stage I gastric cancer, and overlapping and unspecified subsite (hazard ratio = 1.85; 95% CI = 1.14; 3.00) compared to distal tumors. CONCLUSION: Tumor EBV positivity is a favorable prognostic factor in gastric cancer.
DOI: 10.1097/MEG.0000000000001521
Hipersaite: https://www.ncbi.nlm.nih.gov/pubmed/31569122 
Atsauce Gasenko, E., Isajevs, S., Camargo, M., Offerhaus, G., Poļaka, I., Gulley, M., Skapars, R., Sivins, A., Kojalo, I., Kiršners, A., Santare, D., Pavlova, J., Sjomina, O., Liepina, E., Tzivian, L., Rabkin, C., Leja, M. Clinicopathological Characteristics of Epstein-Barr Virus-Positive Gastric Cancer in Latvia. European Journal of Gastroenterology & Hepatology, 2019, Vol. 31, No. 11, 1328.-1333.lpp. ISSN 1473-5687. Pieejams: doi:10.1097/MEG.0000000000001521
Papildinformācija Citējamību skaits:
ID 30117